AIBioTech works with U.S. FDA to keep Sports X Factor genetic test available to consumers

American International Biotechnology Services (AIBioTech) today announced it is working with the U.S. Food and Drug Administration to keep its Sports X Factor genetic test available to consumers.  The test panel screens athletes and young sports competitors for undiagnosed risk factors and athletic strengths to make awareness of potential health conditions more precise and workouts more effective.  

During a meeting with the FDA on May 20, 2011, representatives from AIBioTech committed to working diligently over the next 30 days to submit a plan for performing studies to support Sports X Factor testing, which will ultimately provide results to the FDA for evaluation and subsequent augmentation of section 201(h) of the Federal Food Drug and Cosmetic Act.

"AIBioTech believes that everyone has a right to their genetic information without a prescription. Our main goal with Sports X Factor is to provide an affordable means for athletes and parents to access genetic information for the purpose of making informed decisions about maximizing performance while minimizing risk," said Bill Miller, CEO of AIBioTech. "We recognize the FDA's attention to thorough compliance and are pleased to cooperate with the organization at a time when human genomics is coming to fruition under the FDA umbrella."